Revenue ₹7,546 Cr (-6% YoY)
0 met · 0 close · 15 missed across 15 tracked promises
View all executive profiles for Dr. Reddy's Laboratories LimitedDr.
0% promises delivered
Based on 15 tracked promises across 12 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
2026-04-??
Revenue ₹7,546 Cr (-6% YoY)
Dr.
neutral
medium
3 missed
Read full analysis →
Q3 FY26
23 Jan 2026
Revenue ₹8,753 Cr (+4.4% YoY)
Dr.
neutral
medium
1 missed
Read full analysis →
Q2 FY26
28 Oct 2025
Revenue ₹8,828 Cr (+9.8% YoY)
Dr.
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q1 FY26
30 Jul 2025
Revenue ₹8,545 Cr (+11% YoY)
Dr.
neutral
medium
3 missed
Read full analysis →
Q4 FY25
30 Apr 2025
Revenue ₹8,506 Cr (+20% YoY)
Dr.
bullish
high
2 missed
Read full analysis →
Q3 FY25
22 Jan 2025
Revenue ₹8,359 Cr (+16% YoY)
Dr.
neutral
medium
3 missed
Read full analysis →
Q2 FY25
23 Oct 2024
Revenue ₹8,038 Cr (+17% YoY)
Dr.
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q1 FY25
24 Jul 2024
Revenue ₹7,673 Cr (+14% YoY)
Dr.
bullish
high
1 missed
Read full analysis →
Q4 FY24
08 May 2024
Revenue ₹7,083 Cr (+12% YoY)
Dr.
bullish
high
1 missed
Read full analysis →
Q3 FY24
24 Jan 2024
Revenue ₹7,215 Cr (+7% YoY)
Dr.
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q2 FY24
25 Oct 2023
Revenue ₹6,880 Cr (+9% YoY)
Dr.
bullish
high
1 missed
Read full analysis →
Q1 FY24
26 Jul 2023
Revenue ₹6,738 Cr (+29% YoY)
Dr.
bullish
high
Scorecard starts after historical backfill
Read full analysis →